Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA

Artikel i vetenskaplig tidskrift
Författare K. Fleshner
Sigrid Carlsson
M. J. Roobol
Publicerad i Nature Reviews Urology
Volym 14
Nummer/häfte 1
Sidor 26-37
ISSN 1759-4812
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi
Sidor 26-37
Språk English
Länkar 10.1038/nrurol.2016.251
Ämnesord services-task-force, primary-care physicians, informed decision-making, united-states, increasing incidence, gleason score, follow-up, age 50, antigen, impact, Urology & Nephrology, tosky al, 1995, jama-journal of the american medical association, v273, p548, neja ss, 2016, j urology, v195, p350
Ämneskategorier Urologi och njurmedicin

Sammanfattning

Guidelines regarding recommendations for PSA screening for early detection of prostate cancer are conflicting. In 2012, the United States Preventive Services Task Force (USPSTF) assigned a grade of D (recommending against screening) for men aged years in 2008 and for men of all ages in 2012. Understanding temporal trends in rates of screening before and after the 2012 recommendation in terms of usage patterns in PSA screening, changes in prostate cancer incidence and biopsy patterns, and how the recommendation has influenced physician's and men's attitudes about PSA screening and subsequent ordering of other screening tests is essential within the scope of prostate cancer screening policy. Since the 2012 recommendation, rates of PSA screening decreased by 3-10% in all age groups and across most geographical regions of the USA. Rates of prostate biopsy and prostate cancer incidence have declined in unison, with a shift towards tumours being of higher grade and stage upon detection. Despite the recommendation, some physicians report ongoing willingness to screen appropriately selected men, and many men report intending to continue to ask for the PSA test from their physician. In the coming years, we expect to have an improved understanding of whether these decreased rates of screening will affect prostate cancer metastasis and mortality.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?